NCT00612456 is a Phase 2 clinical trial of Pazopanib in Macular Degeneration, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00612456?

NCT00612456 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00612456?

Interventions in NCT00612456: Pazopanib.

What condition does NCT00612456 study?

NCT00612456 studies Macular Degeneration.

Is NCT00612456 still recruiting?

NCT00612456 is currently completed. Last updated 20 November 2017.

Are results published for NCT00612456?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-11-20 · How we verify

NCT00612456

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

Completed Phase 2 Results posted Last updated 20 November 2017

What this trial tests

Phase 2 trial testing Pazopanib in Macular Degeneration in 70 participants. Completed in 17 June 2009.

Timeline

5 March 2008

Primary endpoint
1 January 2009

17 June 2009

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	70
Start date	5 March 2008
Primary completion	1 January 2009
Estimated completion	17 June 2009
Sites	27 locations across Belgium, Italy, United States, Australia

Drugs / interventions tested

Pazopanib — full drug profile →

Conditions studied

Macular Degeneration — all drugs for Macular Degeneration →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

50 and older, any sex, with Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Mean Change From Baseline in Central Retinal/Lesion Thickness (CRLT) as Measured by the Carl Zeiss Meditec Stratus Optical Coherence Tomography (OCT) Scanner at Day 29 Primary · Baseline (Day -3 to -1) and Day 29

CRLT was measured by the Carl Zeiss Meditec Stratus OCT scanner based on the manual measurement of the distance between the inner and outer retina, inclusive of subretinal fluid and any choroidal neovascularization (CNV) as measured in the central 1 millimeter (mm) area of the 7 mm Posterior Pole Scan. OCT scans/images were collected by trained and certified photographer and analyzed by investigator. Two datasets were used for analysis namely Last observation carried forward (LOCF) which included missing assessment for a participant who completed at least 7 days of pazopanib eye drop replaced

CRLT as measued by OCT, LOCF data

Group	Value	95% CI
Pazopanib 5 mg/mL TID	7.5	± 110.34
Pazopanib 2 mg/mL TID	10.0	± 83.78
Pazopanib 5 mg/mL Once Daily	31.2	± 85.72

CRLT as measued by OCT, OC data

Group	Value	95% CI
Pazopanib 5 mg/mL TID	7.5	± 110.34
Pazopanib 2 mg/mL TID	3.0	± 85.16
Pazopanib 5 mg/mL Once Daily	9.1	± 69.12

Number of Participants With Complete Ophthalmic Examination Values of Potential Clinical Concern Secondary · Upto follow-up (Day 43)

A complete eye examination was performed to include the following: Examination of eyelids and lashes (including meibomian glands), Pupil, motility and confrontation visual field examination, Slit lamp evaluation of anterior ocular structures (including conjunctiva, tear film, cornea with fluorescein staining, anterior chamber, iris, lens, and anterior vitreous), intraocular pressure (IOP) measurement and Dilated Fundus Examination (Indirect ophthalmoscopy and slit lamp biomicroscopy). Data has been presented in a consolidated format for the total number of participants with values of potential

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0
Pazopanib 2 mg/mL TID	0
Pazopanib 5 mg/mL Once Daily	0

Number of Participants With Vital Sign Data for Systolic Blood Pressure and Diastolic Blood Pressure and Heart Rate of Potential Clinical Concern Secondary · Up to follow up (Day 46)

Vital sign assessments included systolic blood pressure, diastolic blood pressure and heart rate. The potential clinical concern range for systolic blood pressure was \<85 and \> 160 millimeters of mercury, diastolic blood pressure \<45 and \> 100 millimeters of mercury, heart rate \<40 and \>110 beats per minute. Only those parameters for which at least one value of potential clinical importance was reported are summarized. The number of participants with potential clinical important findings at any visit were reported.

Systolic blood pressure

Group	Value	95% CI
Pazopanib 5 mg/mL TID	1
Pazopanib 2 mg/mL TID	4
Pazopanib 5 mg/mL Once Daily	1

Diastolic blood pressure

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0
Pazopanib 2 mg/mL TID	1
Pazopanib 5 mg/mL Once Daily	0

Heart rate

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0
Pazopanib 2 mg/mL TID	0
Pazopanib 5 mg/mL Once Daily	0

Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings Secondary · Day 15 and follow-up (Day 43)

Single 12-lead ECGs were to be obtained at each Day 15 and follow-up Day 43 using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and QTc intervals. ECG findings were defined as abnormal-not clinically significant (A-NCS) and abnormal-clinically significant (A-CS). Data has been presented for the number of participants with A-NCS and A-CS findings.

Day 15, A-NCS

Group	Value	95% CI
Pazopanib 5 mg/mL TID	11
Pazopanib 2 mg/mL TID	11
Pazopanib 5 mg/mL Once Daily	6

Day 15, A-CS

Group	Value	95% CI
Pazopanib 5 mg/mL TID	1
Pazopanib 2 mg/mL TID	0
Pazopanib 5 mg/mL Once Daily	0

Follow-up (Day 43), A-NCS

Group	Value	95% CI
Pazopanib 5 mg/mL TID	7
Pazopanib 2 mg/mL TID	10
Pazopanib 5 mg/mL Once Daily	8

Follow-up (Day 43), A-CS

Group	Value	95% CI
Pazopanib 5 mg/mL TID	2
Pazopanib 2 mg/mL TID	0
Pazopanib 5 mg/mL Once Daily	0

Number of Participants With Clinical Chemistry and Hematology Data of Potential Clinical Concern Secondary · Up to follow-up Day 43

Clinical chemistry parameters assessed included blood urea nitrogen, potassium, calcium, albumin, creatinine, chloride, sodium, total protein, glucose, total carbon dioxide, aspartate amino transferase, alanine amino transferase, direct bilirubin, total bilirubin, alkaline phosphatase and hematology parameters assessed included platelet count, white blood cell count, red blood cell count, reticulocyte count, hemoglobin, mean corpuscle volume, mean corpuscle hemoglobin, mean corpuscle hemoglobin concentration, total neutrophils, lymphocytes, monocytes, eosinophils, basophils. Data has been pres

Glucose high

Group	Value	95% CI
Pazopanib 5 mg/mL TID	4
Pazopanib 2 mg/mL TID	1
Pazopanib 5 mg/mL Once Daily	1

Glucose low

Group	Value	95% CI
Pazopanib 5 mg/mL TID	2
Pazopanib 2 mg/mL TID	0
Pazopanib 5 mg/mL Once Daily	0

Calcium low

Group	Value	95% CI
Pazopanib 5 mg/mL TID	1
Pazopanib 2 mg/mL TID	0
Pazopanib 5 mg/mL Once Daily	0

Potassium high

Group	Value	95% CI
Pazopanib 5 mg/mL TID	1
Pazopanib 2 mg/mL TID	1
Pazopanib 5 mg/mL Once Daily	0

Total bilirubin high

Group	Value	95% CI
Pazopanib 5 mg/mL TID	1
Pazopanib 2 mg/mL TID	0
Pazopanib 5 mg/mL Once Daily	0

Alkaline phosphatase high

Group	Value	95% CI
Pazopanib 5 mg/mL TID	1
Pazopanib 2 mg/mL TID	0
Pazopanib 5 mg/mL Once Daily	0

Lymphocytes low

Group	Value	95% CI
Pazopanib 5 mg/mL TID	1
Pazopanib 2 mg/mL TID	1
Pazopanib 5 mg/mL Once Daily	1

Total neutrophils low

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0
Pazopanib 2 mg/mL TID	0
Pazopanib 5 mg/mL Once Daily	1

Number of Participants With Abnormal Urinalysis Data by Dipstick Analysis Secondary · Day 29 and follow-up (Day 43)

Urinalysis included analysis for urine occult blood, urine glucose, urine ketones and urine proteins via dipstick analysis. Data has been presented for number of participants with abnormal urinalysis results. Only categories with values have been presented.

Urine Occult Blood at Day 29 1 hour, 1+

Group	Value	95% CI
Pazopanib 5 mg/mL TID	1
Pazopanib 2 mg/mL TID	1
Pazopanib 5 mg/mL Once Daily	2

Urine Occult Blood at Day 29 1 hour, 2+

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0
Pazopanib 2 mg/mL TID	1
Pazopanib 5 mg/mL Once Daily	0

Urine Occult Blood at Follow-up, 1+

Group	Value	95% CI
Pazopanib 5 mg/mL TID	1
Pazopanib 2 mg/mL TID	0
Pazopanib 5 mg/mL Once Daily	0

Urine Glucose at Day 29 1 hour, 1+ OR 1/4

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0
Pazopanib 2 mg/mL TID	1
Pazopanib 5 mg/mL Once Daily	1

Urine Glucose at Follow-up, 3+ OR 1 gram/deciliter

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0
Pazopanib 2 mg/mL TID	0
Pazopanib 5 mg/mL Once Daily	1

Urine Protein at Day 29 1 hour, 1+

Group	Value	95% CI
Pazopanib 5 mg/mL TID	2
Pazopanib 2 mg/mL TID	2
Pazopanib 5 mg/mL Once Daily	1

Urine Protein at Day 29 1 hour, 2+

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0
Pazopanib 2 mg/mL TID	1
Pazopanib 5 mg/mL Once Daily	0

Urine Protein at Follow-up, 1+

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0
Pazopanib 2 mg/mL TID	2
Pazopanib 5 mg/mL Once Daily	0

Number of Participants With Ocular Adverse Events, Non-ocular Adverse Events, Serious Ocular Adverse Events and Serious Non-ocular Adverse Events Secondary · Up to follow-up (Day 43)

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospit

Non-Ocular Adverse Events

Group	Value	95% CI
Pazopanib 5 mg/mL TID	10
Pazopanib 2 mg/mL TID	5
Pazopanib 5 mg/mL Once Daily	2

Ocular Adverse Events, Fellow eye

Group	Value	95% CI
Pazopanib 5 mg/mL TID	2
Pazopanib 2 mg/mL TID	0
Pazopanib 5 mg/mL Once Daily	1

Ocular Adverse Events, Study eye

Group	Value	95% CI
Pazopanib 5 mg/mL TID	9
Pazopanib 2 mg/mL TID	2
Pazopanib 5 mg/mL Once Daily	3

Non-Ocular Serious Adverse Events

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0
Pazopanib 2 mg/mL TID	1
Pazopanib 5 mg/mL Once Daily	0

Change From Baseline in Best Corrected Visual Acuity (BCVA) [Number of Letter Read on Standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) Charts at Day 29 Secondary · Baseline (Day -3 to -1) and Day 29

BCVA was measured in the study eye using the ETDRS grading charts consists of at least 24 to 78 letters placed at a test distance of 4 meters. There were 7 cut off points in visual acuity on ETDRS grading chart: 15 to 29, 10 to 14, 5 to 9, -4 to 4, -5 to -9, -10 to -14 and -15 to -29 letters. Grade 15 to 29 indicates no impairment in vision and grade -15 to -29 indicates worst impairment in vision. Analyses were done for two sub-efficacy-populations. One sub-efficacy population included all participants in the efficacy population with a YES for retinal angiomatous proliferation (RAP)/retinal c

BCVA at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	4.3	± 5.95
Pazopanib 2 mg/mL TID	0.8	± 8.38
Pazopanib 5 mg/mL Once Daily	0.0	± 2.05

YES for RAP/RCA NONE field from DARC FA at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	4.8	± 5.67
Pazopanib 2 mg/mL TID	1.7	± 7.43
Pazopanib 5 mg/mL Once Daily	-0.1	± 2.13

YES for eligible field from DARC FA form at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	3.5	± 5.26
Pazopanib 2 mg/mL TID	0.8	± 7.39
Pazopanib 5 mg/mL Once Daily	0.3	± 1.38

Number of Participants With Change in Retinal Morphology (Cystoid Spaces, Subretinal Fluid and Retinal Pigment Epithelial Detachment) as Determined by OCT Secondary · Day 29

OCT was used for the determination of retinal morphology changes in the study eye which included assessments of cystoids spaces (cyst like spaces in the inner layers of the retina), subretinal fluid (an exudate between the retina and choroid from various sources including the vitreous cavity, subarachnoid space, or abnormal vessels) and pigment epithelial detachment (retinal pigment epithelium separates from the underlying Bruch's membrane due to the presence of blood, serous exudate, drusen, or a neovascular membrane). Data has been presented for number of participants with retinal morphology

Cystoid spaces at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	9
Pazopanib 2 mg/mL TID	10
Pazopanib 5 mg/mL Once Daily	5

Pigment epithelial detachment at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	1
Pazopanib 2 mg/mL TID	2
Pazopanib 5 mg/mL Once Daily	1

Subretinal fluid at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	2
Pazopanib 2 mg/mL TID	4
Pazopanib 5 mg/mL Once Daily	2

Number of Participants With Change in Characteristics (Fibrosis, Atrophy, Blood) as Measured by Fundus Photography (FP) Secondary · Day 29

Fundus photography involves capturing of images of the center of the very back inner wall of the eye - the retina, optic nerve, macula and main retinal blood vessels. The parameters assessment were heme subretinal hemorrhage (absence or presence at the location), heme intraretinal hemorrhage (absence or presence at the location), subretinal fluid (absence or presence at location), fibrosis (absence or presence at location), atrophy (absence or presence of atrophic changes) and pigment ((absence or presence at location). A protocol set of fundus photographs were obtained at Day 29. Images were

Heme subretinal hemorrhage at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	14
Pazopanib 2 mg/mL TID	14
Pazopanib 5 mg/mL Once Daily	7

Heme intraretinal hemorrhage at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	7
Pazopanib 2 mg/mL TID	1
Pazopanib 5 mg/mL Once Daily	1

Subretinal fluid at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	26
Pazopanib 2 mg/mL TID	22
Pazopanib 5 mg/mL Once Daily	11

Fibrosis at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	2
Pazopanib 2 mg/mL TID	2
Pazopanib 5 mg/mL Once Daily	1

Atrophy at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	6
Pazopanib 2 mg/mL TID	6
Pazopanib 5 mg/mL Once Daily	5

Pigment at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	23
Pazopanib 2 mg/mL TID	20
Pazopanib 5 mg/mL Once Daily	11

Change From Baseline in Neovascular Size, Total Lesion Size, Fluorescein Angiography (FA) Leakage Area of Measurement, FA Blood Area of Measurement as Measured by FA at Day 29 Secondary · Baseline (Day -3 to -1) and Day 29

FA uses FP to capture images of injected dye circulating throughout the retinal blood vessels to assess leaking, swelling or circulation problems caused by various eye diseases like diabetic retinopathy and wet macular degeneration. The parameters assessed were CNV size, Classic CNV size, FA blood area of measurement, FA leakage area of measurement and total lesion size. A protocol fluorescein angiogram was to be obtained at Day 29. Images were evaluated by investigator for eligibility determination, and by a central reading center for determination of PD effect. Data has been presented for ch

CNV size at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0.6	± 1.67
Pazopanib 2 mg/mL TID	0.44	± 2.04
Pazopanib 5 mg/mL Once Daily	0.7	± 1.96

Classic CNV size at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0.2	± 0.90
Pazopanib 2 mg/mL TID	1.5	± 1.62
Pazopanib 5 mg/mL Once Daily	0.7	± 0.81

FA blood area of measurement at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	-0.2	± 0.75
Pazopanib 2 mg/mL TID	1.0	± 1.87
Pazopanib 5 mg/mL Once Daily	0.4	± 0.82

FA leakage area of measurement at Day 29

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0.8	± 1.77
Pazopanib 2 mg/mL TID	0.8	± 2.06
Pazopanib 5 mg/mL Once Daily	0.6	± 1.88

Total lesion size

Group	Value	95% CI
Pazopanib 5 mg/mL TID	0.5	± 1.57
Pazopanib 2 mg/mL TID	1.2	± 2.37
Pazopanib 5 mg/mL Once Daily	0.7	± 1.86

Plasma Pharmacokinetic Parameter Maximum Observed Concentration (Cmax) Secondary · Day 15 and Day 22

Blood samples for analysis of plasma pazopanib concentrations were collected over 6 hours after an ocular dose of pazopanib on Day 15 or Day 22. PK analyses of plasma pazopanib concentration-time data were conducted using non-compartmental Model 200 (for extravascular administration) of WinNonlin Professional Edition version 5.2. Data has been presented for pharmacokinetic parameter Cmax at Day 15 and Day 22.

Day 15

Group	Value	95% CI
Pazopanib 5 mg/mL TID	56.104	± 85.38
Pazopanib 2 mg/mL TID	21.142	± 75.53

Day 22

Group	Value	95% CI
Pazopanib 2 mg/mL TID	17.680	± NA

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to follow-up (Day 43). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Pazopanib 5 mg/mL TID

Serious: 0/27 (0%)

Deaths: 0/27

Pazopanib 2 mg/mL TID

Serious: 1/27 (4%)

Deaths: 0/27

Pazopanib 5 mg/mL Once Daily

Serious: 0/16 (0%)

Deaths: 0/16

Serious adverse events (1 terms)

Reaction	System	Pazopanib 5 mg/mL TID	Pazopanib 2 mg/mL TID	Pazopanib 5 mg/mL Once Daily
Atrial fibrillation	Cardiac disorders	—	—	—

Other adverse events (11 terms — click to expand)

Reaction	System	Pazopanib 5 mg/mL TID	Pazopanib 2 mg/mL TID	Pazopanib 5 mg/mL Once Daily
Headache	Nervous system disorders	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—
Nausea	Gastrointestinal disorders	—	—	—
Retinal disorder	Eye disorders	—	—	—
Vision blurred	Eye disorders	—	—	—
Detachment of retinal pigment epithelium	Eye disorders	—	—	—
Myodesopsia	Eye disorders	—	—	—
Visual acuity reduced	Eye disorders	—	—	—
Visual impairment	Eye disorders	—	—	—
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	—	—	—
Hypertension	Vascular disorders	—	—	—

Most-reported serious reactions: Atrial fibrillation.

Data from ClinicalTrials.gov NCT00612456 adverse events section.

Sponsor's own description

This is a 28 day study to evaluate the pharmacodynamic effect of pazopanib eye drops on the central retinal thickness of AMD patients

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Recent Advances in Age-Related Macular Degeneration Therapies.
Fabre M, Mateo L, Lamaa D, Baillif S, et al · · 2022 · cited 68× · PMID 36014339 · DOI 10.3390/molecules27165089
Anti-angiogenic Therapy for Retinal Disease.
Paulus YM, Sodhi A. · · 2017 · cited 43× · PMID 27783271 · DOI 10.1007/164_2016_78
FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders.
Lui A, Vanleuven J, Perekopskiy D, Liu D, et al · · 2022 · cited 15× · PMID 36558997 · DOI 10.3390/ph15121546
Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy.
Huang X, Zhang L, Fu Y, Zhang M, et al · · 2023 · cited 3× · PMID 37288355 · DOI 10.3389/fbioe.2023.1199922
Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024).
Aliashrafzadeh H, Liu D, De Alba S, Akbar I, et al · · 2025 · PMID 40708570 · DOI 10.37349/eds.2025.1008116

Verify or expand the search:

Other trials of Pazopanib

Trials testing the same drug.

NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07087158 — A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT04199026 — Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sa · NA · recruiting
NCT03850730 — Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia · Phase 1, PHASE2 · unknown
NCT05432791 — Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped W · Phase 2, PHASE3 · active not recruiting

Other recruiting trials for Macular Degeneration

Currently open trials in the same condition.

NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
NCT07085533 — Natural History Study of Inherited Retinal Diseases · recruiting
NCT06805474 — A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT · recruiting
NCT06779773 — A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy · recruiting
NCT06635148 — A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Se · Phase 2 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00612456 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 20 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00612456.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing